Quarry LP Takes $95,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Quarry LP acquired a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,000 shares of the company’s stock, valued at approximately $95,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC lifted its position in Kymera Therapeutics by 5.8% during the 3rd quarter. FMR LLC now owns 5,109,141 shares of the company’s stock worth $241,816,000 after acquiring an additional 282,301 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Kymera Therapeutics by 85.8% in the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock worth $37,754,000 after purchasing an additional 368,394 shares during the period. Eventide Asset Management LLC lifted its position in shares of Kymera Therapeutics by 9.9% during the 3rd quarter. Eventide Asset Management LLC now owns 507,902 shares of the company’s stock worth $24,039,000 after purchasing an additional 45,803 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Kymera Therapeutics by 11.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 453,377 shares of the company’s stock valued at $21,458,000 after purchasing an additional 47,507 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Kymera Therapeutics by 15.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 402,385 shares of the company’s stock valued at $12,012,000 after buying an additional 53,176 shares during the last quarter.

Insider Activity

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 15.82% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

KYMR has been the subject of several research reports. UBS Group reduced their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Leerink Partners restated an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Monday, September 9th. BMO Capital Markets initiated coverage on shares of Kymera Therapeutics in a research report on Friday. They set a “market perform” rating and a $55.00 price objective for the company. Stephens began coverage on Kymera Therapeutics in a research report on Monday, November 18th. They set an “overweight” rating and a $65.00 target price on the stock. Finally, Truist Financial reaffirmed a “buy” rating and issued a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $53.50.

Kymera Therapeutics Stock Up 5.9 %

NASDAQ:KYMR opened at $46.67 on Friday. The firm has a market cap of $3.02 billion, a PE ratio of -19.94 and a beta of 2.16. Kymera Therapeutics, Inc. has a 12 month low of $21.20 and a 12 month high of $53.27. The company’s 50-day moving average price is $46.40 and its two-hundred day moving average price is $42.54.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. During the same period in the prior year, the company earned ($0.90) EPS. Kymera Therapeutics’s revenue for the quarter was down 20.9% on a year-over-year basis. On average, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.